In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Nuevolution AS

Executive Summary

Nuevolution is a Danish biotechnology company that aims to generate an ultra-large library of small molecules more than a million times larger than the largest existing industry libraries. By applying its Chemetics evolution-mimicing screening approach Nuevolution hopes to very rapidly select the best ligands to any drug target.

You may also be interested in...



Astex's Pyramid Scheme

Astex's latest deal with Schering further distances the firm from infrastructure-heavy structural biology players. Astex hopes that by applying its fragment-based approach to solving key discovery problems among a handful of much sought-after targets-rather than solving many target structures or offering its capability on a service basis-it can sign higher value deals and prevent itself from becoming a victim of the field's commoditization.

Sunesis Pharmaceuticals Inc.

The drawbacks associated with protein drugs--including the injectable mode of delivery and the high costs of goods--have led a number of biotech and pharmaceutical companies to use their protein engineering capabilities for small molecule drug discovery. Fledging Sunesis Pharmaceuticals Inc. has leapt into the fray with what its management believes is a unique combination of robust proprietary technology and integrated capabilities in medicinal chemistry and protein engineering.

Hijacking The Messenger

Recent excitement around exosomes underscores their potential to solve drug delivery challenges that have limited the power and applicability of the biopharma industry’s growing arsenal of therapeutic modalities. 

Topics

Related Companies

UsernamePublicRestriction

Register

LL111109

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel